Eclipse Surgical Technologies, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Company elects to bypass pursuit of an expanded indication for the Eclipse TMR 2000 transmyocardial revascularization solid-state laser system for use in conjunction with coronary artery bypass grafting following a review of its regulatory strategy, announced March 15. The device was approved for TMR alone in February 1999 (1"The Gray Sheet" Feb. 15, 1999, p. 3). "FDA approved labeling is adequate," Eclipse says, and "the physician can best decide how to use the laser system within the approved labeling." A 263-patient randomized study published in the March issue of the Journal of Thoracic and Cardiovascular Surgery comparing the combination therapy to CABG alone showed "angina relief and exercise treadmill improvement were indistinguishable between groups at 12 months of follow-up"
You may also be interested in...
Eclipse Surgical TMR Laser Shipments Commence Following FDA Approval
Shipments of Eclipse Surgical Technologies' Eclipse 2000 transmyocardial revascularization laser system began "immediately" following FDA approval, announced Feb. 11, at a price of $295,000 each, according to the firm.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.